The estimated Net Worth of Elvia Cowan is at least $2.88 Milion dollars as of 3 September 2024. Elvia Cowan owns over 5,000 units of Vaxcyte stock worth over $2,012,447 and over the last 2 years Elvia sold PCVX stock worth over $865,106.
Elvia has made over 4 trades of the Vaxcyte stock since 2024, according to the Form 4 filled with the SEC. Most recently Elvia exercised 5,000 units of PCVX stock worth $129,600 on 3 September 2024.
The largest trade Elvia's ever made was selling 11,678 units of Vaxcyte stock on 29 February 2024 worth over $865,106. On average, Elvia trades about 4,446 units every 31 days since 2023. As of 3 September 2024 Elvia still owns at least 17,723 units of Vaxcyte stock.
You can see the complete history of Elvia Cowan stock trades at the bottom of the page.
Elvia's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS, CA, 94070.
Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ... oraz Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Vaxcyte executives and other stock owners filed with the SEC include: